Tangeretin sensitizes cisplatin-resistant human ovarian cancer cells through downregulation of phosphoinositide 3-kinase/Akt signaling pathway

Cancer Research

Volumn 69, Issue 23, 2009, Pages 8910-8917

  Arafa, El Shaimaa A ^a,b   Zhu, Qianzheng ^a   Barakat, Bassant M ^a   Wani, Gulzar ^a   Zhao, Qun ^a   El Mahdy, Mohamed A ^a   Wani, Altaf A ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b Beni Suef University   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE; CISPLATIN; GLYCOGEN SYNTHASE KINASE 3BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BAD; PROTEIN KINASE B; SMALL INTERFERING RNA; TANGERETIN;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER RESISTANCE; CANCER THERAPY; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; DRUG POTENTIATION; DRUG RESPONSE; DRUG SENSITIZATION; ENZYME INHIBITION; FEMALE; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; OVARY CANCER; PRIORITY JOURNAL;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL DIVISION; CELL GROWTH PROCESSES; CISPLATIN; DOWN-REGULATION; DRUG ADMINISTRATION SCHEDULE; DRUG SYNERGISM; FEMALE; FLAVONES; G2 PHASE; GLYCOGEN SYNTHASE KINASE 3; HUMANS; ONCOGENE PROTEIN V-AKT; OVARIAN NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 71549170831     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-1543     Document Type: Article

References (44)

1. Stewart JJ, White JT, Yan X, et al. Proteins associated with Cisplatin resistance in ovarian cancer cells identified by quantitative proteomic technology and integrated with mRNA expression levels. Mol Cell Proteomics 2006;5:433-443
2. Balch C, Huang TH, Brown R, Nephew KP. The epigenetics of ovarian cancer drug resistance and resensitization. Am J Obstet Gynecol 2004;191:1552-1572 (Pubitemid 39491180)
3. Previati M, Lanzoni I, Corbacella E, et al. Cisplatin-induced apoptosis in human promyelocytic leukemia cells. Int J Mol Med 2006;18:511-516
4. Ohmichi M, Hayakawa J, Tasaka K, Kurachi H, Murata Y. Mechanisms of platinum drug resistance. Trends Pharmacol Sci 2005;26:113-116
5. Franke TF, Hornik CP, Segev L, Shostak GA, Sugimoto C. PI3K/Akt and apoptosis: size matters. Oncogene 2003;22:8983-8998
6. Cantley LC, Auger KR, Carpenter C, et al. Oncogenes and signal transduction. Cell 1991;64:281-302.
7. Cantley LC, Neel BG. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci U S A 1999;96:4240-4245
8. Ikeda S, Kishida S, Yamamoto H, et al. Axin, a negative regulator of the Wnt signaling pathway, forms a complex with GSK-3β and β-catenin and promotes GSK- 3β-dependent phosphorylation of β-catenin. EMBO J 1998;17:1371-1384 (Pubitemid 28105516)
9. Pap M, Cooper GM. Role of glycogen synthase kinase-3 in the phosphatidylinositol 3-Kinase/Akt cell survival pathway. J Biol Chem 1998;273:19929-19932 (Pubitemid 28377539)
10. Diehl JA, Cheng M, Roussel MF, Sherr CJ. Glycogen synthase kinase-3β regulates cyclin D1 proteolysis and subcellular localization. Genes Dev 1998;12:3499-3511 (Pubitemid 28553242)
11. Gajewski TF, Thompson CB. Apoptosis meets signal transduction: elimination of a BAD influence. Cell 1996; 87:589-592
12. Franke TF, Cantley LC. Apoptosis. A Bad kinase makes good. Nature 1997;390:116-117
13. del PL, Gonzalez-Garcia M, Page C, Herrera R, Nunez G. Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. Science 1997;278:687-689 (Pubitemid 27464966)
14. Datta SR, Dudek H, Tao X, et al. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 1997;91:231-241 (Pubitemid 27456390)
15. Romashkova JA, Makarov SS. NF-κB is a target of AKT in anti-apoptotic PDGF signalling. Nature 1999; 401:86-90. (Pubitemid 29418448)
16. Ozes ON, Mayo LD, Gustin JA, et al. NF-κB activation by tumour necrosis factor requires the Akt serine-threonine kinase. Nature 1999;401:82-85 (Pubitemid 29418447)
17. Luo JL, Kamata H, Karin M. IKK/NF-κB signaling: balancing life and death-a new approach to cancer therapy. J Clin Invest 2005;115:2625-2632 (Pubitemid 41434385)
18. Luo JL, Kamata H, Karin M. The anti-death machinery in IKK/NF-κB signaling. J Clin Immunol 2005;25: 541-550
19. Li Y, Ahmed F, Ali S, et al. Inactivation of nuclear factor κB by soy isoflavone genistein contributes to increased apoptosis induced by chemotherapeutic agents in human cancer cells. Cancer Res 2005;65:6934-6942 (Pubitemid 41060733)
20. Walle T. Methoxylated flavones, a superior cancer chemopreventive flavonoid subclass? Semin Cancer Biol 2007;17:354-362
21. Bailly C. Topoisomerase I poisons and suppressors as anticancer drugs. Curr Med Chem 2000;7:39-58. (Pubitemid 30395448)
22. Wang IK, Lin-Shiau SY, Lin JK. Induction of apoptosis by apigenin and related flavonoids through cytochrome c release and activation of caspase-9 and caspase-3 in leukaemia HL-60 cells. Eur J Cancer 1999; 35:1517-1525
23. Markovits J, Linassier C, Fosse P, et al. Inhibitory effects of the tyrosine kinase inhibitor genistein on mammalian DNA topoisomerase II. Cancer Res 1989;49: 5111-5117 (Pubitemid 19239354)
24. Darwanto A, Tanjung M, Darmadi MO. Cytotoxic mechanism of flavonoid from Temu Kunci (Kaempferia pandurata) in cell culture of human mammary carcinoma. Clin Hemorheol Microcirc 2000;23:185-190 (Pubitemid 32274603)
25. Rong Y, Yang EB, Zhang K, Mack P. Quercetin-induced apoptosis in the monoblastoid cell line U937 in vitro and the regulation of heat shock proteins expression. Anticancer Res 2000;20:4339-4345 (Pubitemid 32141783)
26. Chen YC, Shen SC, Lee WR, et al. Wogonin and fisetin induction of apoptosis through activation of caspase 3 cascade and alternative expression of p21 protein in hepatocellular carcinoma cells SK-HEP-1. Arch Toxicol 2002;76:351-359
27. Wenzel U, Kuntz S, Brendel MD, Daniel H. Dietary flavone is a potent apoptosis inducer in human colon carcinoma cells. Cancer Res 2000;60:3823-3831 (Pubitemid 32204574)
28. Iwashita K, Kobori M, Yamaki K, Tsushida T. Flavonoids inhibit cell growth and induce apoptosis in B16 melanoma 4A5 cells. Biosci Biotechnol Biochem 2000; 64:1813-1820
29. Konig A, Schwartz GK, Mohammad RM, Al-Katib A, Gabrilove JL. The novel cyclin-dependent kinase inhibitor flavopiridol downregulates Bcl-2 and induces growth arrest and apoptosis in chronic B-cell leukemia lines. Blood 1997;90:4307-4312 (Pubitemid 27508436)
30. Yin F, Giuliano AE, Van Herle AJ. Signal pathways involved in apigenin inhibition of growth and induction of apoptosis of human anaplastic thyroid cancer cells (ARO). Anticancer Res 1999;19:4297-4303
31. Kandaswami C, Perkins E, Soloniuk DS, Drzewiecki G, Middleton E, Jr. Antiproliferative effects of citrus flavonoids on a human squamous cell carcinoma in vitro. Cancer Lett 1991;56:147-152
32. Nijveldt RJ, van NE, van Hoorn DE, et al. Flavonoids: a review of probable mechanisms of action and potential applications. Am J Clin Nutr 2001;74:418-425
33. El-Mahdy MA, Zhu Q, Wang QE, Wani G, Wani AA. Thymoquinone induces apoptosis through activation of caspase-8 and mitochondrial events in p53-null myeloblastic leukemia HL-60 cells. Int J Cancer 2005;117: 409-417 (Pubitemid 41429564)
34. Sarkar FH, Li Y. Using chemopreventive agents to enhance the efficacy of cancer therapy. Cancer Res 2006; 66:3347-3350
35. Bava SV, Puliappadamba VT, Deepti A, et al. Sensitization of taxol-induced apoptosis by curcumin involves down-regulation of nuclear factor-κB and the serine/ threonine kinase Akt and is independent of tubulin polymerization. J Biol Chem 2005;280:6301-6308 (Pubitemid 40341176)
36. Morley KL, Ferguson PJ, Koropatnick J. Tangeretin and nobiletin induce G1 cell cycle arrest but not apoptosis in human breast and colon cancer cells. Cancer Lett 2007;251:168-178 (Pubitemid 46589774)
37. Pan MH, Chen WJ, Lin-Shiau SY, Ho CT, Lin JK. Tangeretin induces cell-cycle G1 arrest through inhibiting cyclin-dependent kinases 2 and 4 activities as well as elevating Cdk inhibitors p21 and p27 in human colorectal carcinoma cells. Carcinogenesis 2002; 23:1677-1684
38. Hirano T, Abe K, Gotoh M, Oka K. Citrus flavone tangeretin inhibits leukaemic HL-60 cell growth partially through induction of apoptosis with less cytotoxicity on normal lymphocytes. Br J Cancer 1995;72: 1380-1388 (Pubitemid 26002646)
39. Jones NA, Turner J, McIlwrath AJ, Brown R, Dive C. Cisplatin- and paclitaxel-induced apoptosis of ovarian carcinoma cells and the relationship between bax and bak up-regulation and the functional status of p53. Mol Pharmacol 1998;53:819-826 (Pubitemid 28244068)
40. Vasey PA, Jones NA, Jenkins S, Dive C, Brown R. Cisplatin, camptothecin, and taxol sensitivities of cells with p53-associated multidrug resistance. Mol Pharmacol 1996;50:1536-1540 (Pubitemid 26425109)
41. Behrens BC, Hamilton TC, Masuda H, et al. Characterization of a cis-diamminedichloroplatinum(II)- resistant human ovarian cancer cell line and its use in evaluation of platinum analogues. Cancer Res 1987;47: 414-418 (Pubitemid 17009602)
42. Chen KH, Weng MS, Lin JK. Tangeretin suppresses IL-1β-induced cyclooxygenase (COX)-2 expression through inhibition of p38 MAPK, JNK, AKT activation in human lung carcinoma cells. Biochem Pharmacol 2007;73:215-227
43. Datla KP, Christidou M, Widmer WW, Rooprai HK, Dexter DT. Tissue distribution and neuroprotective effects of citrus flavonoid tangeretin in a rat model of Parkinson's disease. Neuroreport 2001;12: 3871-3875 (Pubitemid 33105188)
44. Vanhoecke BW, Delporte F, Van BE, et al. A safety study of oral tangeretin and xanthohumol administration to laboratory mice. In vivo 2005;19:103-107